Xiangxue Pharmaceutical Co.,Ltd.: history, ownership, mission, how it works & makes money

Born as Guangzhou Luogang Pharmaceutical Factory in 1986, Xiangxue Pharmaceutical (listed on the Shenzhen Growth Enterprise Market under ticker 300147 on December 15, 2010) has evolved from a regional drug producer to a diversified healthcare group driving the modernization of traditional Chinese medicine-pivoting in 2012 toward biomedical innovation and clinical immunotherapy while expanding into proprietary Chinese medicines, functional health products and medical devices; its ownership structure as of December 31, 2016 showed founders and investment vehicles led by Chairman Wang Yonghui and Chen Shumei controlling 36.98% of shares, with institutional stakes including the National Social Security Fund at 4.09%, a Luogang civilian-owned water company at 4.06% and Central Huijin at 1.51%, and the company now operates through 18 subsidiaries across Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia, runs GMP and GAP-certified bases, develops TCR-T cancer therapies via Xiangxue Life Sciences and international collaborations (notably with Athenex Inc.), and derives revenue from sales of antiviral oral liquids, proprietary medicines, beverages, medical devices, licensing deals and commercialization of innovative biopharmaceuticals.

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ) - Intro

• Founded: 1986 (as Guangzhou Luogang Pharmaceutical Factory)
• Name change: 1997 - Guangzhou Xiangxue Pharmaceutical Co., Ltd.
• Listed: December 15, 2010 - Shenzhen Stock Exchange GEM (300147)
• Strategic pivot: 2012 - focus on biomedical technologies and clinical immunotherapy

• Pharmaceutical product sales - prescription drugs, OTC and modernized TCM formulations sold via hospitals, pharmacies and distributors.
• Biologics and cell therapy R&D/commercialization - including clinical-stage immunotherapies licensed or co-developed with partners.
• Medical devices and health products - development and sales of device-assisted therapies and consumer health supplements.
• Contract manufacturing and toll production - leveraging manufacturing sites to provide capacity for third parties.
• Licensing, milestone and collaboration revenue - income from technology transfers, research collaborations and regional partnerships.

• R&D pipeline drives long-term value: discovery → preclinical → clinical trials → regulatory approval → commercialization.
• Manufacturing scale converts approved products into recurring revenue via bulk drug and finished-dose production.
• Partnerships and licensing reduce development risk and provide upfront/milestone payments plus royalties.
• Vertical product mix (TCM, small-molecule drugs, biologics, devices) balances cash generation and higher-margin innovative assets.

• Established collaborative innovation system linking in-house R&D with academic institutions and global partners to accelerate cell therapy programs.
• Invests in clinical immunotherapy pipelines and platform technologies intended to generate high-value biologic assets and licensing opportunities.
• Seeks to modernize TCM by applying standardized production, quality control, and clinical validation to traditional formulations.

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ): History

• Founded in Guangzhou; expanded from local production to national sales and select export markets.
• Developed a mixed portfolio: OTC consumer healthcare, prescription generics, and herbal/TCM products.
• Pursued manufacturing scale, upstream API sourcing and downstream branded marketing to capture margin.

• Wang Yonghui and Chen Shumei investment vehicles - combined 36.98% ownership.
• Wang Yonghui - serves as Chairman and General Manager.
• National Social Security Fund - combined 4.09% via two accounts.
• Civilian-owned water supply company (Luogang, Guangzhou) - 4.06% stake.
• Central Huijin Investment - 1.51% stake.
• Additional holdings by private equity funds managed by banks (minority stakes).

• Mission: develop accessible, clinically effective pharmaceutical products for common diseases, with emphasis on respiratory and antiviral segments.
• Strategy: combine scale manufacturing, portfolio of OTC and prescription products, and targeted M&A/alliances to broaden market reach.

• Product sales: revenue primarily from sales of branded OTC medicines, prescription generics and TCM products to hospitals, pharmacies and distributors.
• Contract manufacturing (CMO): capacity utilization by third-party clients for API/formulation production generates manufacturing margin.
• Distribution & channel management: revenue uplift via regional distributor networks and retail pharmacy partnerships.
• R&D and product life-cycle: investing in registration and incremental formulation improvements to sustain price and market access.
• Financial/asset leverage: institutional and government-related shareholders provide balance-sheet credibility for supply contracts and potential financing.

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ): Ownership Structure

• Mission: Modernize traditional Chinese medicine by integrating research, production and sales to deliver high-quality healthcare products and services.
• Values: Independent innovation, IP ownership, scientific research, international cooperative innovation and commitment to the "big health" industry.
• Strategic focus areas: New TCM tablets, proprietary Chinese medicines, functional health products, biomedical engineering and life-science R&D.

• R&D-driven pipeline: invests in formulation modernization, clinical validation and proprietary IP to create differentiated TCM products.
• Manufacturing scale: owns production facilities for tablets, capsules and health supplements, generating gross-margin revenue from finished goods sales.
• Multi-channel distribution: sells through hospitals, pharmacies, e-commerce platforms and direct-to-consumer channels to diversify sales mix.
• Therapeutic & consumer portfolios: revenue split across prescription TCM, OTC/proprietary medicines and functional health products, supplemented by biomedical engineering contracts and licensing/IP monetization.

• Strengthen independent innovation and IP-expand patented products and proprietary brands.
• Scale high-margin proprietary TCM and functional-health product lines to lift overall gross margin.
• Deepen clinical evidence and regulatory approvals to expand hospital and institutional adoption.
• Expand international cooperation in R&D and distribution to access overseas markets.

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ): Mission and Values

• Core focus: R&D and commercialization of new traditional Chinese medicine tablets and proprietary Chinese patent medicines.
• Quality control: Uses GAP-certified herb planting bases and GMP-certified production facilities to ensure raw material traceability and consistent manufacturing quality.
• Geographic footprint: Operations across Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia via 18 subsidiaries.
• Product diversification: Functional health beverages, medical adhesives, endoscopic trocars and other medical devices complementing the pharmaceutical portfolio.
• Advanced biotherapy: Wholly-owned Xiangxue Life Sciences focusing on T-cell receptor (TCR)-based therapies for cancer and immuno-oncology platforms.
• International partnerships: Collaborations with companies such as Athenex Inc. to co-develop TCR-T and other novel cancer therapies.

• R&D-driven product pipeline: Internal research teams and Xiangxue Life Sciences advance formulation, clinical development and biologics (TCR-T) programs, creating proprietary IP and pipeline assets that can be commercialized or partnered.
• Manufacturing and quality assurance: GAP-secured raw materials move to GMP-certified production bases where tablets, capsules, beverages and medical devices are manufactured to regulatory standards, enabling margin capture from in-house production.
• Sales and distribution: Pharmaceutical sales rely on hospital channels, retail pharmacies and regional distributors across listed provinces; health beverages and daily-consumption functional products access broader retail channels and e-commerce.
• Medical device business: Devices such as adhesives and endoscopic trocars expand revenue streams with hospital procurement and surgical supply channels.
• Partnerships and licensing: Strategic collaborations (e.g., with Athenex) enable co-development, licensing fees, milestone payments and potential royalties from novel oncology therapeutics.
• Asset monetization and equity returns: Clinical-stage biologics and cell therapy assets held by Xiangxue Life Sciences present opportunities for out-licensing, equity investments or M&A exits that can produce non-operating income.

• Subsidiaries: 18 legal entities supporting regional manufacturing, distribution and R&D.
• Regional presence: Active operations in 8 Chinese provinces/municipalities (Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan, Ningxia).
• Manufacturing & cultivation: Operates multiple GMP-certified production bases and GAP-certified medicinal herb planting bases to secure supply chain quality.
• Biotech platform: Xiangxue Life Sciences is wholly owned and focused on TCR-based immunotherapies; external collaborations accelerate clinical development.

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ): How It Works

• Core product lines: proprietary TCM oral liquids (antiviral and respiratory formulas), health supplements, functional beverages, and a range of medical devices and consumables.
• R&D and biotech: in-house and partnered development of innovative biopharmaceuticals and oncology candidates intended for commercialization in Greater China.
• Commercialization channels: a mix of hospital procurement, pharmacy retail chains, e‑commerce platforms, and regional distributors across mainland China, Hong Kong and Macao.
• Licensing & partnerships: strategic agreements with foreign biopharma firms to obtain rights to develop/commercialize innovative oncology and specialty products in China.

• Direct product sales - the largest revenue contributor from proprietary TCM formulations, functional beverages and medical devices sold through retail and institutional channels.
• Licensing and milestone income - fees and potential milestone payments from licensing-out or in-licensing arrangements (including oncology collaborations).
• R&D service and co-development income - collaborative programs with domestic and international partners that share development costs and future revenue upside.
• Exports and Greater China commercialization - revenues derived from Hong Kong and Macao, and selected export markets via partnerships.

• Athenex Inc. collaboration: Xiangxue secured rights to develop and commercialize certain oncology products in China, Hong Kong and Macao, giving Xiangxue a pathway to add high-value oncology revenues once regulatory approvals and launches occur.

• Discovery & formulation: modernization of TCM formulas and screening of new actives; internal labs and partnerships support preclinical work.
• Clinical & regulatory: phased clinical and regulatory pathways for biopharma candidates; TCM products follow CFDA/NMPA registration routes and post-market surveillance.
• Manufacturing & QA: company-owned GMP manufacturing lines for liquids, beverages and medical consumables ensure supply and margin control.
• Commercial launch & distribution: multi-channel sales (hospitals, pharmacies, e-commerce, distributors) ramps volume; marketing invests in brand and physician outreach for specialty products.
• Monetization via licensing: for higher-risk, higher-reward oncology assets, Xiangxue may partner with or license from international firms (e.g., Athenex) to share development risk and secure commercialization rights.

• Modernizing TCM - reformulation, quality controls, and scientific validation to capture premium pricing and institutional buyers.
• Biotech pipeline - advancing oncology and specialty biologics through partnerships and internal R&D to open new high-margin revenue streams.
• Channel diversification - expanding e‑commerce and cross‑border channels to reduce single-channel dependence.
• Partnerships & licensing - leveraging in‑licensing of international assets and out‑licensing of domestic know‑how to drive milestone and royalty income.

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ): How It Makes Money

• Core revenue streams: sales of finished pharmaceutical products (TCM injections, oral formulations, topical products), bulk drug production for third parties, and margin from hospital and retail drug channels.
• Growth/innovation streams: licensing royalties, milestone payments and future sales from partnered oncology and cell-therapy programs (including collaborations with international firms such as Athenex Inc.).
• Service streams: contract manufacturing and research services for domestic and overseas biotech clients.

• Market position: Recognized as a leading enterprise in the modernization of traditional Chinese medicine, with a diversified product portfolio spanning established TCM lines and newer biologics.
• R&D & innovation: Sustained investment in R&D (notably T-cell receptor-based therapies and other precision oncology assets) positions the company toward higher-margin specialty medicines over time.
• Strategic collaborations: International partnerships (e.g., Athenex Inc.) provide access to novel drug platforms, clinical know-how and potential overseas markets, amplifying future revenue levers beyond domestic TCM sales.
• Quality & compliance: Manufacturing scale, GMP certifications and clinical-stage assets underpin competitive advantage in hospital procurement and export channels.
• Future outlook: Ongoing R&D investment, pipeline advancement in personalized therapies and deeper international alliances support a positive growth trajectory, with potential margin expansion as specialty products scale.